Lilly sues two more med spas over copycat weight-loss drugs

Eli Lilly said on Jan. 13 that it has filed lawsuits against two medical spas, Thrive Health and Wellness LLC and Valhalla Vitality LLC, over unapproved products the companies claim contain tirzepatide, the active ingredient in Lilly's diabetes drug Mounjaro and weight-loss drug Zepbound ^[1]. The suit against Thrive was filed in the district court of Colorado, and the suit against Valhalla was filed in the Eastern District of New York ^[1].

Lilly says both companies made false claims about the safety, purity or effectiveness of their products ^[1]. According to the complaint, Thrive's marketing describes its product, called "MEGALean – Premium Tirzepatide Injections," as clinically tested to help with weight loss and blood sugar control ^[1]. Lilly says Valhalla's website and ads imply that its version of tirzepatide has been proven safe and effective for weight loss ^[1]. Neither company responded to a Reuters request for comment ^[1].

These two cases are not isolated. Lilly has now sued more than two dozen medical spas, wellness centers and compounding pharmacies over products claiming to contain tirzepatide ^[1]. The company is Indianapolis-based, and tirzepatide is approved under two brand names: Mounjaro for type 2 diabetes and Zepbound for weight loss ^[1].

The legal fight centers on compounding, a practice in which pharmacies or other facilities mix or alter drug ingredients to create medicines ^[1]. Federal rules allow compounded versions of a drug to be sold when the original is in short supply ^[1]. Lilly's lawsuits argue that the products sold by these spas go beyond that allowance, making unsupported claims and using Lilly's branded language to sell unapproved formulations ^[1].

Why it matters for patients

For people considering a compounded tirzepatide product, these lawsuits are a signal that the source and marketing of a product may not match what regulators have approved. Lilly's complaints allege that businesses have advertised specific claims of clinical testing or proven safety and effectiveness that the company disputes ^[1]. Patients who see marketing language promising results similar to Mounjaro or Zepbound may not be getting a product with the same testing, purity, or manufacturing oversight as the branded drug, based on what Lilly alleges in its filings ^[1].

The scale of Lilly's enforcement, more than two dozen entities sued to date, suggests the copycat tirzepatide market has been large enough to draw sustained legal attention ^[1]. That in turn suggests patients weighing options outside the brand-name supply chain are entering a legal and regulatory gray area, one where the compounding exception for drug shortages is central to the dispute ^[1]. Whether a given compounded product falls within that exception, or outside it as Lilly alleges in these cases, is often not something a patient can independently verify from marketing materials alone.

What happens next

The sources reviewed here do not include outcomes for the Thrive or Valhalla cases, filed in Colorado and the Eastern District of New York respectively ^[1]. It is not yet known from available reporting how these specific suits will be resolved or what practical effect, if any, they will have on availability of compounded tirzepatide products. The summary accompanying this development describes a "quarterly pattern of enforcement actions through 2025," indicating Lilly is expected to continue filing similar suits, though specific future dates or targets are not detailed in the sources provided.